Clinical Trial Update: A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of IMC-002 for active systemic lupus erythematosus has not yet begun recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• IMC-002

Snippet

Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Conditions: Systemic Lupus Erythematosus | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING